Epstein-Barr virus entry utilizing HLA-DP or HLA-DQ as a coreceptor.
Epstein-Barr virus (EBV) glycoprotein gp350/gp220 association with cellular CD21 facilitates virion attachment to B lymphocytes. Membrane fusion requires the additional interaction between virion gp42 and cellular HLA-DR. This binding is thought to catalyze membrane fusion through a further association with the gp85-gp25 (gH-gL) complex. Cell lines expressing CD21 but lacking expression of HLA class II molecules are resistant to infection by a recombinant EBV expressing enhanced green fluorescent protein. Surface expression of HLA-DR, HLA-DP, or HLA-DQ confers susceptibility to EBV infection on resistant cells that express CD21. Therefore, HLA-DP or HLA-DQ can substitute for HLA-DR and serve as a coreceptor in EBV entry.
Haan
K M
KM
Department of Microbiology-Immunology, Northwestern University Medical School, Chicago, Illinois 60611, USA.
Kwok
W W
WW
Longnecker
R
R
Speck
P
P
D002460:Cell Line; D005434:Flow Cytometry; D017930:Genes, Reporter; D049452:Green Fluorescent Proteins; D006682:HLA-DP Antigens / Q000032:analysis / Q000378:metabolism*; D006683:HLA-DQ Antigens / Q000032:analysis / Q000378:metabolism*; D004854:Herpesvirus 4, Human / Q000472:pathogenicity*; D008164:Luminescent Proteins / Q000235:genetics; D017464:Receptors, Complement 3d / Q000378:metabolism; D011991:Receptors, Virus / Q000502:physiology*
D006682:HLA-DP Antigens; D006683:HLA-DQ Antigens; D008164:Luminescent Proteins; D017464:Receptors, Complement 3d; D011991:Receptors, Virus; D049452:Green Fluorescent Proteins